ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals (ANIP) filed a Form 144 notifying a proposed Rule 144 sale of 50,000 common shares to be handled by Morgan Stanley Smith Barney LLC on 08/12/2025 on the NASDAQ. The filing lists an aggregate market value of $4,303,590.00 and 21,699,636 shares outstanding, making the proposed sale roughly 0.23% of outstanding shares and implying an approximate price of $86.07 per share. The shares were reported as acquired the same day by stock option exercise from the issuer with cash payment. The filing reports no securities sold in the past three months. The extract does not include the filer identity or a dated signature in the provided content.
ANIP Q2-25 revenue jumped 53% YoY to $211.4 m, propelled by Cortrophin Gel (+66% to $81.6 m) and the first full quarter of ILUVIEN/YUTIQ sales ($22.3 m) acquired with Alimera. Generics grew 22% to $90.3 m.
Gross margin widened to 64.7% (58.2% LY) while SG&A climbed 55% on integration and commercial scale-up. Operating income rose to $13.9 m (6.6% margin) from $5.2 m; net income swung to $8.5 m, delivering diluted EPS of $0.36 versus a $0.14 loss. Six-month revenue is $408.5 m (+48%) with EPS of $1.05.
Cash reached $217.8 m as operating cash flow tripled to $110.8 m. Total debt remains high at $621.6 m (incl. $306.9 m converts), leaving net debt of ≈$404 m and leverage near 2.9× LTM sales. Intangible assets of $520 m and goodwill of $60.5 m reflect the Alimera deal; contingent consideration stands at $18.6 m.
Management stresses ongoing rare-disease momentum, manufacturing synergies and expanded market reach, but notes risks around debt covenants, rising rebate liabilities and Alimera integration.
ANI Pharmaceuticals, Inc. furnished an earnings press release covering its financial results for the second quarter ended June 30, 2025. The company disclosed that it issued this press release on August 8, 2025, and attached it as Exhibit 99.1 to the report. The information related to these results is being furnished rather than filed under securities laws, which means it is not automatically subject to certain liability provisions or incorporated into other regulatory filings unless specifically referenced.